Egle Tx
3 known investors
Egle Therapeutics develops targeted immunotherapy drugs by leveraging regulatory T cell (Treg) biology to treat autoimmune diseases and cancer. The company creates drug candidates that selectively modulate Tregs to inhibit them in tumors or expand them in inflamed tissues.
Biotechin /egle-tx
Founders & leadership
MD
Michel DetheuxChairman
FK
Fiorella KotsiasChief Scientific Officer
BV
Bernard VanhoveChief Development Officer